We’re sorry, something doesn't seem to be working properly.

Please try refreshing the page. If that doesn't work, please contact support so we can address the problem.

We’re sorry, something doesn't seem to be working properly.

Please try refreshing the page. If that doesn't work, please contact support so we can address the problem.

Antipsychotika | SpringerLink

We’re sorry, something doesn't seem to be working properly.

Please try refreshing the page. If that doesn't work, please contact support so we can address the problem.

Skip to main content
SpringerLink
Log in

Antipsychotika

    We’re sorry, something doesn't seem to be working properly.

    Please try refreshing the page. If that doesn't work, please contact support so we can address the problem.

  • First Online:
Kompendium der Psychiatrischen Pharmakotherapie

We’re sorry, something doesn't seem to be working properly.

Please try refreshing the page. If that doesn't work, please contact support so we can address the problem.

  • 1669 Accesses

Zusammenfassung

Indikationen, Wirkungsweise, Nebenwirkungen und Risiken, Kontraindikationen und Interaktionen werden für die Antipsychotika im allgemeinen Teil und dann für jedes Arzneimittel spezifisch im Präparateteil beschrieben. Ein Schwerpunkt liegt in der ausführlichen Darstellung der Risiken und Nebenwirkungen der Antipsychotika.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 54.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 69.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Literatur

  • Arasteh O, Nomani H, Baharara H et al (2020) Antipsychotic drugs and risk of developing venous thromboembolism and pulmonary embolism: a systematic review and meta-analysis. Curr Vasc Pharmacol 18(6):632–643

    Article  CAS  PubMed  Google Scholar 

  • Arranz B, Garriga M, Bernardo M et al (2022) Clinical practice guideline on pharmacological and psychological management of adult patients with schizophrenia spectrum disorders and a comorbid substance use. Adicciones 34(2):110–127

    Article  PubMed  Google Scholar 

  • Bartoli F, Riboldi I, Bachi B et al (2021) Efficacy of cannabidiol for ∆-9-tetrahydrocannabinol-induced psychotic symptoms, schizophrenia, and cannabis use disorders: a narrative review. J Clin Med 10(6):1303

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Bighelli I, Rodolico A, Siafis S et al (2022) Antipsychotic polypharmacy reduction versus polypharmacy continuation for people with schizophrenia. Cochrane Database Syst Rev 8(8):CD14383

    PubMed  Google Scholar 

  • Burk BG, Donaldson V, Jackson CW (2022) Paliperidone-associated sialorrhea: a case report with review of current literature. J Clin Psychopharmacol 42(5):480–484

    Article  PubMed  Google Scholar 

  • Burschinski A, Schneider-Thoma J, Chiocchia V et al (2023) Metabolic side effects in persons with schizophrenia during mid- to long-term treatment with antipsychotics: a network meta-analysis of randomized controlled trials. World Psychiatry 22(1):116–128

    Article  PubMed  PubMed Central  Google Scholar 

  • Ceraso A, Lin JJ, Schneider-Thoma J et al (2022) Maintenance treatment with antipsychotic drugs in schizophrenia: a Cochrane systematic review and meta-analysis. Schizophr Bull 48(4):738–740

    Article  PubMed  PubMed Central  Google Scholar 

  • Chen B, Wang C, Xu X et al (2020) Risk of prolonged corrected QT interval with amisulpride therapy for renal function management in patients with schizophrenia. J Clin Psychopharmacol 40(5):482–486

    Article  CAS  PubMed  Google Scholar 

  • Comai S, Fuamba Y, Rivolta MC, Gobbi G (2021) Lifetime cannabis use disorder is not associated with lifetime impulsive behavior and aevere violence in patients with schizophrenia spectrum disorders from a high-security hospital. J Clin Psychopharmacol 41(6):623–628

    Article  PubMed  Google Scholar 

  • Correll CU, Kim E, Sliwa JK et al (2021) Pharmacokinetic characteristics of long-acting injectable antipsychotics for schizophrenia: an overview. CNS Drugs 35(1):39–59

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Das N, Faheem A, Shoib S (2022) The facts and fiction of olanzapine-samidorphan fixed dose combination. Alpha Psychiatry 23(4):210–211

    Article  PubMed  PubMed Central  Google Scholar 

  • Davis JM, Jin H (2022) Choosing an optimal antipsychotic dose for relapse prevention. Schizophr Bull 48(4):723–725

    Article  PubMed  PubMed Central  Google Scholar 

  • de Leon J, Schoretsanitis G, Smith RL et al (2022) An international adult guideline for making clozapine titration safer by using six ancestry-based personalized dosing titrations, CRP, and clozapine levels. Pharmacopsychiatry 55(02):e1

    Article  PubMed  Google Scholar 

  • Demjaha A, Lappin JM, Stahl D et al (2017) Antipsychotic treatment resistance in first-episode psychosis: prevalence, subtypes and predictors. Psychol Med 47(11):1981–1989

    Article  CAS  PubMed  Google Scholar 

  • DGPPN (Deutsche Gesellschaft für Psychiatrie, Psychotherapie und Nervenheilkunde e. V.) (Hrsg) (2019) S3-Leitlinie Schizophrenie. AWMF-Register Nr. 038-009. Langfassung, Stand: 15. März 2019. https://www.awmf.org/leitlinien/detail/ll/038-009.html. Zugegriffen: 13. Mai 2023

  • Dunk LR, Annan LJ, Andrews CD (2006) Rechallenge with clozapine following leucopenia or neutropenia during previous therapy. Br J Psychiatry 188:255–263

    Article  PubMed  Google Scholar 

  • Galling B, Vernon JA, Pagsberg AK et al (2018) Efficacy and safety of antidepressant augmentation of continued antipsychotic treatment in patients with schizophrenia. Acta Psychiatr Scand 137(3):187–205

    Article  CAS  PubMed  Google Scholar 

  • Greger J, Aladeen T, Lewandowski E (2021) Comparison of the metabolic characteristics of newer second generation antipsychotics: brexpiprazole, lurasidone, asenapine, cariprazine, and iloperidone with olanzapine as a comparator. J Clin Psychopharmacol 41(1):5–12

    Article  CAS  PubMed  Google Scholar 

  • Guinart D, Misawa F, Rubio JM et al (2021) A systematic review and pooled, patient-level analysis of predictors of mortality in neuroleptic malignant syndrome. Acta Psychiatr Scand 144(4):329–341

    Article  PubMed  Google Scholar 

  • Haller N, Hasan A, Padberg F et al (2022) Transkranielle elektrische Hirnstimulationsverfahren zur Behandlung der Negativsymptomatik bei Schizophrenie [Transcranial electrical brain stimulation methods for treatment of negative symptoms in schizophrenia]. Nervenarzt 93(1):41–50

    Article  PubMed  Google Scholar 

  • Harrow M, Jobe TH, Tong L (2022) Twenty-year effects of antipsychotics in schizophrenia and affective psychotic disorders. Psychol Med 52(13):2681–2691

    Article  PubMed  Google Scholar 

  • He L, Yu Y, Zhang L et al (2022) A real-world study of risk factors for QTc prolongation in schizophrenia patients receiving atypical antipsychotics. J Clin Psychopharmacol 42(1):71–74

    Article  PubMed  Google Scholar 

  • Hirjak D, Meyer-Lindenberg A, Brandt GA, Dreßing H (2022) Differenzialdiagnostische Unterscheidung zwischen substanzinduzierten und primären Psychosen: Empfehlungen für die allgemeinpsychiatrische und forensische Praxis [Differential diagnostic distinction between substance-induced and primary psychoses: recommendations for general psychiatric and forensic practice]. Nervenarzt 93(1):11–23

    Article  PubMed  Google Scholar 

  • Højlund M, Andersen K, Ernst MT et al (2022) Use of low-dose quetiapine increases the risk of major adverse cardiovascular events: results from a nationwide active comparator-controlled cohort study. World Psychiatry 21(3):444–451

    Article  PubMed  PubMed Central  Google Scholar 

  • Hopkins SC, Lew R, Zeni C, Koblan KS (2023) Challenges in the clinical development of non-D2 compounds for schizophrenia. Curr Med Res Opin 39(3):467–471

    Article  CAS  PubMed  Google Scholar 

  • Howes OD, McCutcheon R, Agid O et al (2017) Treatment-resistant schizophrenia: treatment response and resistance in psychosis (TRRIP) working group consensus guidelines on diagnosis and terminology. Am J Psychiatry 174(3):216–229

    Article  PubMed  Google Scholar 

  • Huhn M, Nikolakopoulou A, Schneider-Thoma J et al (2019) Comparative efficacy and tolerability of 32 oral antipsychotics for the acute treatment of adults with multi-episode schizophrenia: a systematic review and network meta-analysis. Lancet 394(10202):939–951

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Kane JM, Schooler NR, Marcy P et al (2020) Effect of long-acting injectable antipsychotics vs usual care on time to first hospitalization in early-phase schizophrenia: a randomized clinical trial. JAMA Psychiatry 77(12):1217–1224 (Erratum in: JAMA Psychiatry 2020 77(12):1310)

    Article  PubMed  Google Scholar 

  • Krause M, Zhu Y, Huhn M et al (2018) Antipsychotic drugs for patients with schizophrenia and predominant or prominent negative symptoms: a systematic review and meta-analysis. Eur Arch Psychiatr Clin Neurosci 268(7):625–639

    Article  Google Scholar 

  • Krause M, Huhn M, Schneider-Thoma J et al (2019) Efficacy, acceptability and tolerability of antipsychotics in patients with schizophrenia and comorbid substance use. A systematic review and meta-analysis. Eur Neuropsychopharmacol 29(1):32–45

    Article  CAS  PubMed  Google Scholar 

  • Kruizinga J, Liemburg E, Burger H et al (2021) Pharmacological treatment for psychotic depression. Cochrane Database Syst Rev 12(12):CD4044

    PubMed  Google Scholar 

  • Kuhlwilm L, Schönfeldt-Lecuona C et al (2020) The neuroleptic malignant syndrome. Acta Psychiatr Scand 142:233–241

    Article  CAS  PubMed  Google Scholar 

  • Kurdyak P, Mallia E, de Oliveira C et al (2021) Mortality after the first diagnosis of schizophrenia spectrum disorders: a population-based retrospective cohort study. Schizophr Bull 47(3):864–874

    Article  PubMed  PubMed Central  Google Scholar 

  • Lally J, Tully J, Robertson D et al (2016) Augmentation of clozapine with electroconvulsive therapy in treatment resistant schizophrenia: a systematic review and meta-analysis. Schizophr Res 171(1–3):215–224

    Article  PubMed  Google Scholar 

  • Lally J, McCaffrey C, O’Murchu C et al (2019) Clozapine rechallenge following neuroleptic malignant syndrome: a systematic review. J Clin Psychopharmacol 39(4):372–379

    Article  PubMed  Google Scholar 

  • Leucht S, Davis JM (2017) Do antipsychotic drugs lose their efficacy for relapse prevention over time? Br J Psychiatry 211(3):127–129

    Article  PubMed  Google Scholar 

  • Leucht S, Samara M, Heres S, Davis JM (2016) Dose equivalents for antipsychotic drugs: the DDD method. Schizophr Bull 42(Suppl 1):S90–S94

    Article  PubMed  PubMed Central  Google Scholar 

  • Leucht S, Leucht C, Huhn M et al (2017) Sixty years of placebo-controlled antipsychotic drug trials in acute schizophrenia: systematic review, Bayesian meta-analysis, and meta-regression of efficacy predictors. Am J Psychiatry 174(10):927–942

    Article  PubMed  Google Scholar 

  • Leucht S, Chaimani A, Mavridis D et al (2019) Disconnection of drug-response and placebo-response in acute-phase antipsychotic drug trials on schizophrenia? Meta-regression analysis. Neuropsychopharmacology 44(11):1955–1966

    Article  PubMed  PubMed Central  Google Scholar 

  • Leucht S, Bauer S, Siafis S et al (2021) Examination of dosing of antipsychotic drugs for relapse prevention in patients with stable schizophrenia: a meta-analysis. JAMA Psychiatry 78(11):1238–1248

    Article  PubMed  Google Scholar 

  • Leucht S, Chaimani A, Krause M et al (2022) The response of subgroups of patients with schizophrenia to different antipsychotic drugs: a systematic review and meta-analysis. Lancet Psychiatry 9(11):884–893

    Article  PubMed  Google Scholar 

  • Liu CC, Hsieh MH, Chien YL et al (2023) Guided antipsychotic reduction to reach minimum effective dose (GARMED) in patients with remitted psychosis: a 2-year randomized controlled trial with a naturalistic cohort. Psychol Med. https://doi.org/10.1017/s0033291723000429

    Article  PubMed  Google Scholar 

  • Masood B, Lepping P, Romanov D, Poole R (2018) Treatment of alcohol-induced psychotic disorder (alcoholic hallucinosis) – A systematic review. Alcohol Alcohol 53(3):259–267

    Article  PubMed  Google Scholar 

  • Osoegawa C, Gomes JS, Grigolon RB et al (2018) Non-invasive brain stimulation for negative symptoms in schizophrenia: an updated systematic review and meta-analysis. Schizophr Res 197:34–44

    Article  PubMed  Google Scholar 

  • Ostuzzi G, Bertolini F, Del Giovane C et al (2021) Maintenance treatment with long-acting injectable antipsychotics for people with nonaffective psychoses: a network meta-analysis. Am J Psychiatry 178(5):424–436

    Article  PubMed  Google Scholar 

  • Osugo M, Whitehurst T, Shatalina E et al (2022) Dopamine partial agonists and prodopaminergic drugs for schizophrenia: systematic review and meta-analysis of randomized controlled trials. Neurosci Biobehav Rev 135:104568

    Article  CAS  PubMed  Google Scholar 

  • Paul SM, Yohn SE, Popiolek M et al (2022) Muscarinic acetylcholine receptor agonists as novel treatments for schizophrenia. Am J Psychiatry 179(9):611–627

    Article  PubMed  Google Scholar 

  • Pillinger T, McCutcheon RA, Vano L et al (2020) Comparative effects of 18 antipsychotics on metabolic function in patients with schizophrenia, predictors of metabolic dysregulation, and association with psychopathology: a systematic review and network meta-analysis. Lancet Psychiatry 7(1):64–77

    Article  PubMed  PubMed Central  Google Scholar 

  • Qubad M, Bittner RA (2023) Second to none: rationale, timing, and clinical management of clozapine use in schizophrenia. Ther Adv Psychopharmacol 13:20451253231158152

    Article  PubMed  PubMed Central  Google Scholar 

  • Rahman T, Sahrmann JM, Olsen MA et al (2022) Risk of breast cancer with prolactin elevating antipsychotic drugs: an observational study of US women (ages 18–64 years). J Clin Psychopharmacol 42(1):7–16

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Reichelt L, Efthimiou O, Leucht S, Schneider-Thoma J (2023) Second-generation antipsychotics and seizures – a systematic review and meta-analysis of serious adverse events in randomized controlled trials. Eur Neuropsychopharmacol 68:33–46

    Article  CAS  PubMed  Google Scholar 

  • Santos RT, Mullen S, Crouse EL, Adams KS (2023) Comparison of clozapine doses and tolerability in patients with and without concurrent valproic acid. Ment Health Clin 12(6):336–341

    Article  PubMed  PubMed Central  Google Scholar 

  • Schmidt-Kraepelin C, Feyerabend S, Engelke C et al (2022) Amisulpride and olanzapine combination treatment versus each monotherapy in acutely ill patients with schizophrenia in Germany (COMBINE): a double-blind randomised controlled trial. Lancet Psychiatry 9(4):291–306

    Article  PubMed  Google Scholar 

  • Schneider-Thoma J, Efthimiou O, Huhn M et al (2018) Second-generation antipsychotic drugs and short-term mortality: a systematic review and meta-analysis of placebo-controlled randomised controlled trials. Lancet Psychiatry 5(8):653–663

    Article  PubMed  Google Scholar 

  • Schneider-Thoma J, Chalkou K, Dörries C et al (2022) Comparative efficacy and tolerability of 32 oral and long-acting injectable antipsychotics for the maintenance treatment of adults with schizophrenia: a systematic review and network meta-analysis. Lancet 399(10327):824–836

    Article  CAS  PubMed  Google Scholar 

  • Siskind D, Sharma M, Pawar M et al (2021) Clozapine levels as a predictor for therapeutic response. Acta Psychiatr Scand 144:422–432

    Article  CAS  PubMed  Google Scholar 

  • Taipale H, Solmi M, Lähteenvuo M et al (2021) Antipsychotic use and risk of breast cancer in women with schizophrenia: a nationwide nested case-control study in Finland. Lancet Psychiatry 8(10):883–891

    Article  PubMed  Google Scholar 

  • Taipale H, Tanskanen A, Tiihonen J (2023) Safety of antipsychotic polypharmacy versus monotherapy in a nationwide cohort of 61,889 patients with schizophrenia. Am J Psychiatry 180(5):377–385

    Article  PubMed  Google Scholar 

  • Taylor DM, Smith L, Gee SH et al (2012) Augmentation of clozapine with a second antipsychotic – a meta-analysis. Acta Psychiatr Scand 125:15–24

    Article  CAS  PubMed  Google Scholar 

  • Tiihonen J, Mittendorfer-Rutz E, Torniainen M et al (2016) Mortality and cumulative exposure to antipsychotics, antidepressants, and benzodiazepines in patients with schizophrenia: an observational follow-up study. Am J Psychiatry 173(6):600–606

    Article  PubMed  Google Scholar 

  • Tiihonen J, Mittendorfer-Rutz E, Majak M et al (2017) Real-world effectiveness of antipsychotic treatments in a nationwide cohort of 29.823 patients with schizophrenia. JAMA Psychiatry 74(7):686–693

    Article  PubMed  PubMed Central  Google Scholar 

  • Tiihonen J, Taipale H, Mehtälä J et al (2019) Association of antipsychotic polypharmacy vs monotherapy with psychiatric rehospitalization among adults with schizophrenia. JAMA Psychiatry 76(5):499–507

    Article  PubMed  PubMed Central  Google Scholar 

  • Torniainen M, Mittendorfer-Rutz E, Tanskanen A et al (2015) Antipsychotic treatment and mortality in schizophrenia. Schizophr Bull 41:656–636

    Article  PubMed  Google Scholar 

  • van der Zalm Y, Foldager L, Termorshuizen F et al (2021) Clozapine and mortality: a comparison with other antipsychotics in a nationwide Danish cohort study. Acta Psychiatr Scand 143(3):216–226

    Article  PubMed  Google Scholar 

  • Verdoux H, Quiles C, de Leon J (2023) Risks and benefits of clozapine and lithium co-prescribing: a systematic review and expert recommendations. Schizophr Res. https://doi.org/10.1016/j.schres.2023.03.032

    Article  PubMed  Google Scholar 

  • Wagner E, Kane JM, Correll CU et al (2020) Clozapine combination and augmentation strategies in patients with schizophrenia – Recommendations from an international expert survey among the Treatment Response and Resistance in Psychosis (TRRIP) working Group. Schizophr Bull 46(6):1459–1470

    Article  PubMed  PubMed Central  Google Scholar 

  • Wagner E, Siskind D, Falkai P et al (2023) Clozapine optimization: a delphi consensus guideline from the treatment response and resistance in psychosis working group. Schizophr Bull. https://doi.org/10.1093/schbul/sbaa060

    Article  PubMed  Google Scholar 

  • Weizman S, Shelef A, Bloemhof Bris E, Stryjer R (2021) A double-blind, placebo-controlled trial of bupropion add-on to olanzapine or risperidone in overweight individuals with schizophrenia. J Clin Psychopharmacol 41(6):629–631

    Article  CAS  PubMed  Google Scholar 

  • Williams AM (2018) Coadministration of intramuscular olanzapine and benzodiazepines in agitated patients with mental illness. Ment Health Clin 8(5):208–213

    Article  PubMed  PubMed Central  Google Scholar 

  • Wimberley T, MacCabe JH, Laursen TM et al (2017) Mortality and selfharm in association with clozapine in treatment-resistant schizophrenia. Am J Psychiatry 174:990–998

    Article  PubMed  Google Scholar 

  • Wu H, Siafis S, Hamza T et al (2022) Antipsychotic-induced weight gain: dose-response meta-analysis of randomized controlled trials. Schizophr Bull 48(3):643–654

    Article  PubMed  PubMed Central  Google Scholar 

  • Yeh TC, Correll CU, Yang FC et al (2023) Pharmacological and nonpharmacological augmentation treatments for clozapine-resistant schizophrenia: a systematic review and network meta-analysis with normalized entropy assessment. Asian J Psychiatr 79:103375

    Article  PubMed  Google Scholar 

  • Yoshimura B, Sakamoto S, Sato K et al (2019) Predictors of remission during acute treatment of first-episode schizophrenia patients involuntarily hospitalized and treated with algorithm-based pharmacotherapy: secondary analysis of an observational study. Early Interv Psychiatry 13(3):589–597

    Article  PubMed  Google Scholar 

  • Yunusa I, Alsumali A, Garba AE et al (2019) Assessment of reported comparative effectiveness and safety of atypical antipsychotics in the treatment of behavioral and psychological symptoms of dementia: a network meta-analysis. JAMA Netw Open 2(3):e190828

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Berlin, Deutschland

    Prof. Dr. med. Dr. rer. nat. Matthias J. Müller

  2. Mainz, Deutschland

    Prof. Dr. med. Otto Benkert

Authors
  1. Prof. Dr. med. Dr. rer. nat. Matthias J. Müller
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Prof. Dr. med. Otto Benkert
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Otto Benkert .

Editor information

Editors and Affiliations

  1. ehemals Universitäts-Klinikum Mainz, Mainz, Deutschland

    Otto Benkert

  2. ehemals Universitäts-Klinikum München, München, Deutschland

    Hanns Hippius

Rights and permissions

Reprints and permissions

Copyright information

© 2023 Springer-Verlag GmbH Deutschland, ein Teil von Springer Nature

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Müller, M.J., Benkert, O. (2023). Antipsychotika. In: Benkert, O., Hippius, H. (eds) Kompendium der Psychiatrischen Pharmakotherapie. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-662-67685-1_3

Download citation

  • DOI: https://doi.org/10.1007/978-3-662-67685-1_3

  • Published:

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-662-67684-4

  • Online ISBN: 978-3-662-67685-1

  • eBook Packages: Medicine (German Language)

Publish with us

Policies and ethics

Search

Navigation